Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Summary

This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and obinutuzumab may help to control disease progression in CLL patients who have not received treatment for CLL.

Timeline

Start

2020-08-25

Primary completion

2027-06-30

Completion

2027-06-30

Drugs

Indications